Cannabidiol for COVID-19 Patients with Mild to Moderate Symptoms (CANDIDATE Study): A Randomized, Double-Blind, Placebo-Controlled Clinical Trial
José Alexandre S Crippa, Julia Cozar Pacheco, Antonio W Zuardi, Francisco S Guimarães, Alline Cristina Campos, Flávia De Lima Osório, Sonia Regina Loureiro, Rafael G Dos Santos, José Diogo S Souza, Juliana Mayumi Ushirohira, Rafael Rinaldi Ferreira, Karla Cristinne Mancini Costa, Davi Silveira Scomparin, Franciele Franco Scarante, Isabela Pires-Dos-Santos, Raphael Mechoulam, Flávio Kapczinski, Benedito A L Fonseca, Danillo L A Esposito, Afonso Dinis Costa Passos, Amaury Lelis Dal Fabbro, Fernando Bellissimo-Rodrigues, Eurico Arruda, Sandro Scarpelini, Maristela Haddad Andraus, Julio Cesar Nather Junior, Danilo Tadao Wada, Marcel Koenigkam-Santos, Antonio Carlos Santos, Geraldo Busatto Filho, Jaime E C Hallak
Cannabis and Cannabinoid Research, doi:10.1089/can.2021.0093
Importance: Owing to its anti-inflammatory properties and antiviral ''in vitro'' effect against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), cannabidiol (CBD) has been proposed as a potential treatment for coronavirus disease 2019 (COVID-19). Objective: To investigate the safety and efficacy of CBD for treating patients with mild to moderate COVID-19. Design: Randomized, parallel-group, double-blind, placebo-controlled clinical trial conducted between July 7 and October 16, 2020, in two sites in Brazil. Setting: Patients were recruited in an emergency room. Participants: Block randomized patients (1:1 allocation ratio-by a researcher not directly involved in data collection) with mild and moderate COVID-19 living in Ribeira ˜o Preto, Brazil, seeking medical consultation, and those who voluntarily agreed to participate in the study. Interventions: Patients received 300 mg of CBD or placebo added to standard symptomatic care during 14 days. Main Outcome and Measure: The primary outcome was reduction or prevention of the deterioration in clinical status from mild/moderate to severe/critical measured with the COVID-19 Scale or the natural course of the resolution of typical clinical symptoms. Primary study outcome was assessed on days 14, 21, and 28 after enrollment. Results: A total of 321 patients were recruited and assessed for eligibility, and 105 were randomly allocated either in CBD (n = 49) or in placebo (n = 42) group. Ninety-one participants were included in the analysis of efficacy. There were no baseline between-group differences regarding disease severity (v 2 = 0.025, p = 0.988) and median time to symptom resolution (12 days [95% confidence interval, CI, 6.5-17.5] in the CBD group, 9 days [95% CI,
References
Anil, Shalev, Vinayaka, Cannabis compounds exhibit antiinflammatory activity in vitro in COVID-19-related inflammation in lung epithelial cells and pro-inflammatory activity in macrophages, Sci Rep
Bergamaschi, Queiroz, Chagas, Cannabidiol reduces the anxiety induced by simulated public speaking in treatmentnaı ¨ve social phobia patients, Neuropsychopharmacology
Biali, Broers, Besson, Cannabinoids and COVID-19, Med Cannabis Cannabinoids
Byrareddy, Mohan, SARS-CoV2 induced respiratory distress: can cannabinoids be added to anti-viral therapies to reduce lung inflammation?, Brain Behav Immun
Campos, Brant, Miranda, Cannabidiol increases survival and promotes rescue of cognitive function in a murine model of cerebral malaria, Neuroscience
Campos, Ferreira, Guimara, Fs, Cannabidiol blocks long-lasting behavioral consequences of predator threat stress: possible involvement of 5HT1A receptors, J Psychiatr Res
Campos, Ortega, Palazuelos, The anxiolytic effect of cannabidiol on chronically stressed mice depends on hippocampal neurogenesis: involvement of the endocannabinoid system, Int J Neuropsychopharmacol
China, National Health Commission of the People's Republic of China
Crippa, Guimara ˜es, Campos, Translational investigation of the therapeutic potential of cannabidiol (CBD): toward a new age, Front Immunol
Crippa, Pacheco, Zuardi, Guimara ˜es, Campos et al., for the Cannabidiol for COVID-19 Patients (CANDIDATE) Trial Investigators (2021) Cannabidiol for COVID-19 patients with mild to moderate symptoms (CANDIDATE study): a randomized, double-blind, placebo-controlled clinical trial, Cannabis and Cannabinoid Research X:X
Dong, Tang, Wang, The role of imaging in the detection and management of COVID-19: a review, IEEE Rev Biomed Eng
Dos-Santos-Pereira, ˜es, Bel, Cannabidiol prevents LPS-induced microglial inflammation by inhibiting ROS/ NF-jB-dependent signaling and glucose consumption, Glia
Esposito, Pesce, Seguella, The potential of cannabidiol in the COVID-19 pandemic, Br J Pharmacol
Fu, Kong, Wang, The clinical implication of dynamic neutrophil to lymphocyte ratio and D-dimer in COVID-19: a retrospective study in Suzhou China, Thromb Res
Jimeno, Ventura, Castellano, Prognostic implications of neutrophil-lymphocyte ratio in COVID-19, Eur J Clin Invest
Khodadadi, Salles, ´l, Jarrahi, Cannabidiol modulates cytokine storm in acute respiratory distress syndrome induced by simulated viral infection using synthetic RNA, Cannabis Cannabinoid Res
Long, Zeng, Zhang, Short-term outcomes of COVID-19 and risk factors for progression, Eur Respir J
Mabou Tagne, Pacchetti, Sodergren, Cannabidiol for viral diseases: hype or hope? Cannabis Cannabinoid, Res
Malinowska, Baranowska-Kuczko, Kicman, Opportunities, challenges and pitfalls of using cannabidiol as an adjuvant drug in COVID-19, Int J Mol Sci
Masataka, Anxiolytic effects of repeated cannabidiol treatment in teenagers with social anxiety disorders, Front Psychol
Mecha, Feliu, ˜igo, Cannabidiol provides long-lasting protection against the deleterious effects of inflammation in a viral model of multiple sclerosis: a role for A2A receptors, Neurobiol Dis
Moreno, Desousa, Souza, Factor structure, reliability, and item parameters of the Brazilian-Portuguese version of the GAD-7 questionnaire, Temas Psicol
Oso, Vilela Mendes, Crippa, Study of the discriminative validity of the PHQ-9 and PHQ-2 in a sample of Brazilian women in the context of primary health care, Perspect Psychiatr Care
Pacheco, Souza, Hallak, Cannabidiol as a treatment for mental health outcomes among health care workers during the coronavirus disease pandemic, J Clin Psychopharmacol
Raj, Park, Cho, Assessment of antiviral potencies of cannabinoids against SARS-CoV-2 using computational and in vitro approaches, Int J Biol Macromol
Richardson, Hirsch, Narasimhan, Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City area, JAMA
Salles, ´l, Khodadadi, Jarrahi, Cannabidiol (CBD) modulation of apelin in acute respiratory distress syndrome, J Cell Mol Med
Sonego, Prado, Vale, Cannabidiol prevents haloperidolinduced vacuos chewing movements and inflammatory changes in mice via PPARc receptors, Brain Behav Immun
Stamps, Bartoshuk, Heilman, A brief olfactory test for Alzheimer's disease, J Neurol Sci
Suryavanshi, Kovalchuk, Kovalchuk, Cannabinoids as key regulators of inflammasome signaling: a current perspective, Front Immunol
Vuolo, Abreu, Michels, Cannabidiol reduces airway inflammation and fibrosis in experimental allergic asthma, Eur J Pharmacol
Zanelati, Biojone, Moreira, Antidepressant-like effects of cannabidiol in mice: possible involvement of 5-HT 1A receptors, Br J Pharmacol
{ 'indexed': {'date-parts': [[2022, 1, 16]], 'date-time': '2022-01-16T12:25:53Z', 'timestamp': 1642335953220},
'reference-count': 30,
'publisher': 'Mary Ann Liebert Inc',
'license': [ { 'start': { 'date-parts': [[2021, 10, 7]],
'date-time': '2021-10-07T00:00:00Z',
'timestamp': 1633564800000},
'content-version': 'tdm',
'delay-in-days': 0,
'URL': 'https://www.liebertpub.com/nv/resources-tools/text-and-data-mining-policy/121/'}],
'content-domain': {'domain': [], 'crossmark-restriction': False},
'short-container-title': ['Cannabis and Cannabinoid Research'],
'DOI': '10.1089/can.2021.0093',
'type': 'journal-article',
'created': {'date-parts': [[2021, 10, 9]], 'date-time': '2021-10-09T21:02:13Z', 'timestamp': 1633813333000},
'source': 'Crossref',
'is-referenced-by-count': 1,
'title': [ 'Cannabidiol for COVID-19 Patients with Mild to Moderate Symptoms (CANDIDATE Study): A '
'Randomized, Double-Blind, Placebo-Controlled Clinical Trial'],
'prefix': '10.1089',
'author': [ { 'ORCID': 'http://orcid.org/0000-0001-9520-6746',
'authenticated-orcid': False,
'given': 'José Alexandre S.',
'family': 'Crippa',
'sequence': 'first',
'affiliation': [ { 'name': 'Department of Neuroscience and Behavior, Ribeirão Preto Medical '
'School, University of São Paulo, Ribeirão Preto, Brazil.'},
{ 'name': 'National Institute for Science and Technology—Translational '
'Medicine, São Paulo, Brazil.'}]},
{ 'given': 'Julia Cozar',
'family': 'Pacheco',
'sequence': 'additional',
'affiliation': [ { 'name': 'Department of Neuroscience and Behavior, Ribeirão Preto Medical '
'School, University of São Paulo, Ribeirão Preto, Brazil.'}]},
{ 'given': 'Antonio W.',
'family': 'Zuardi',
'sequence': 'additional',
'affiliation': [ { 'name': 'Department of Neuroscience and Behavior, Ribeirão Preto Medical '
'School, University of São Paulo, Ribeirão Preto, Brazil.'},
{ 'name': 'National Institute for Science and Technology—Translational '
'Medicine, São Paulo, Brazil.'}]},
{ 'given': 'Francisco S.',
'family': 'Guimarães',
'sequence': 'additional',
'affiliation': [ { 'name': 'National Institute for Science and Technology—Translational '
'Medicine, São Paulo, Brazil.'},
{ 'name': 'Department of Pharmacology, Ribeirão Preto Medical School, '
'University of São Paulo, Ribeirão Preto, Brazil.'}]},
{ 'given': 'Alline Cristina',
'family': 'Campos',
'sequence': 'additional',
'affiliation': [ { 'name': 'Department of Pharmacology, Ribeirão Preto Medical School, '
'University of São Paulo, Ribeirão Preto, Brazil.'}]},
{ 'given': 'Flávia de Lima',
'family': 'Osório',
'sequence': 'additional',
'affiliation': [ { 'name': 'Department of Neuroscience and Behavior, Ribeirão Preto Medical '
'School, University of São Paulo, Ribeirão Preto, Brazil.'},
{ 'name': 'National Institute for Science and Technology—Translational '
'Medicine, São Paulo, Brazil.'}]},
{ 'given': 'Sonia Regina',
'family': 'Loureiro',
'sequence': 'additional',
'affiliation': [ { 'name': 'Department of Neuroscience and Behavior, Ribeirão Preto Medical '
'School, University of São Paulo, Ribeirão Preto, Brazil.'}]},
{ 'given': 'Rafael G.',
'family': 'dos Santos',
'sequence': 'additional',
'affiliation': [ { 'name': 'Department of Neuroscience and Behavior, Ribeirão Preto Medical '
'School, University of São Paulo, Ribeirão Preto, Brazil.'},
{ 'name': 'National Institute for Science and Technology—Translational '
'Medicine, São Paulo, Brazil.'}]},
{ 'given': 'José Diogo S.',
'family': 'Souza',
'sequence': 'additional',
'affiliation': [ { 'name': 'Department of Neuroscience and Behavior, Ribeirão Preto Medical '
'School, University of São Paulo, Ribeirão Preto, Brazil.'}]},
{ 'given': 'Juliana Mayumi',
'family': 'Ushirohira',
'sequence': 'additional',
'affiliation': [ { 'name': 'Department of Neuroscience and Behavior, Ribeirão Preto Medical '
'School, University of São Paulo, Ribeirão Preto, Brazil.'}]},
{ 'given': 'Rafael Rinaldi',
'family': 'Ferreira',
'sequence': 'additional',
'affiliation': [ { 'name': 'Department of Pharmacology, Ribeirão Preto Medical School, '
'University of São Paulo, Ribeirão Preto, Brazil.'}]},
{ 'given': 'Karla Cristinne',
'family': 'Mancini Costa',
'sequence': 'additional',
'affiliation': [ { 'name': 'Department of Pharmacology, Ribeirão Preto Medical School, '
'University of São Paulo, Ribeirão Preto, Brazil.'}]},
{ 'given': 'Davi Silveira',
'family': 'Scomparin',
'sequence': 'additional',
'affiliation': [ { 'name': 'Department of Pharmacology, Ribeirão Preto Medical School, '
'University of São Paulo, Ribeirão Preto, Brazil.'}]},
{ 'given': 'Franciele Franco',
'family': 'Scarante',
'sequence': 'additional',
'affiliation': [ { 'name': 'Department of Pharmacology, Ribeirão Preto Medical School, '
'University of São Paulo, Ribeirão Preto, Brazil.'}]},
{ 'given': 'Isabela',
'family': 'Pires-Dos-Santos',
'sequence': 'additional',
'affiliation': [ { 'name': 'Department of Pharmacology, Ribeirão Preto Medical School, '
'University of São Paulo, Ribeirão Preto, Brazil.'}]},
{ 'given': 'Raphael',
'family': 'Mechoulam',
'sequence': 'additional',
'affiliation': [ { 'name': 'Department of Medicinal Chemistry and Natural Products, The '
'Institute for Drug Research, School of Pharmacy, The Hebrew '
'University of Jerusalem, Jerusalem, Israel.'}]},
{ 'given': 'Flávio',
'family': 'Kapczinski',
'sequence': 'additional',
'affiliation': [ { 'name': 'National Institute for Science and Technology—Translational '
'Medicine, São Paulo, Brazil.'},
{ 'name': 'Department of Psychiatry and Behavioural Neurosciences, McMaster '
"University and St. Joseph's Healthcare Hamilton, Hamilton, "
'Canada.'},
{ 'name': 'Graduate Program in Psychiatry and Behavioral Sciences, '
'Department of Psychiatry, Faculty of Medicine, Federal '
'University of Rio Grande do Sul, Porto Alegre, Brazil.'}]},
{ 'given': 'Benedito A.L.',
'family': 'Fonseca',
'sequence': 'additional',
'affiliation': [ { 'name': 'Department of Internal Medicine, Ribeirão Preto Medical School, '
'University of São Paulo, Ribeirão Preto, Brazil.'}]},
{ 'given': 'Danillo L.A.',
'family': 'Esposito',
'sequence': 'additional',
'affiliation': [ { 'name': 'Department of Internal Medicine, Ribeirão Preto Medical School, '
'University of São Paulo, Ribeirão Preto, Brazil.'}]},
{ 'given': 'Afonso Dinis Costa',
'family': 'Passos',
'sequence': 'additional',
'affiliation': [ { 'name': 'Department of Social Medicine, Ribeirão Preto Medical School, '
'University of São Paulo, Ribeirão Preto, Brazil.'}]},
{ 'given': 'Amaury Lelis',
'family': 'Dal Fabbro',
'sequence': 'additional',
'affiliation': [ { 'name': 'Department of Social Medicine, Ribeirão Preto Medical School, '
'University of São Paulo, Ribeirão Preto, Brazil.'}]},
{ 'given': 'Fernando',
'family': 'Bellissimo-Rodrigues',
'sequence': 'additional',
'affiliation': [ { 'name': 'Department of Social Medicine, Ribeirão Preto Medical School, '
'University of São Paulo, Ribeirão Preto, Brazil.'}]},
{ 'given': 'Eurico',
'family': 'Arruda',
'sequence': 'additional',
'affiliation': [ { 'name': 'Department of Cell and Molecular Biology, Ribeirão Preto Medical '
'School, University of São Paulo, Ribeirão Preto, Brazil.'}]},
{ 'given': 'Sandro',
'family': 'Scarpelini',
'sequence': 'additional',
'affiliation': [ { 'name': 'Department of Surgery and Anatomy, Ribeirão Preto Medical '
'School, University of São Paulo, Ribeirão Preto, Brazil.'}]},
{ 'given': 'Maristela Haddad',
'family': 'Andraus',
'sequence': 'additional',
'affiliation': [{'name': 'Chromatox Laboratory Ltda., São Paulo, Brazil.'}]},
{ 'given': 'Julio Cesar',
'family': 'Nather Junior',
'sequence': 'additional',
'affiliation': [ { 'name': 'Department of Medical Imaging, Hematology, and Clinical '
'Oncology, Ribeirão Preto Medical School, University of São '
'Paulo, Ribeirão Preto, Brazil.'}]},
{ 'given': 'Danilo Tadao',
'family': 'Wada',
'sequence': 'additional',
'affiliation': [ { 'name': 'Department of Medical Imaging, Hematology, and Clinical '
'Oncology, Ribeirão Preto Medical School, University of São '
'Paulo, Ribeirão Preto, Brazil.'}]},
{ 'given': 'Marcel',
'family': 'Koenigkam-Santos',
'sequence': 'additional',
'affiliation': [ { 'name': 'Department of Medical Imaging, Hematology, and Clinical '
'Oncology, Ribeirão Preto Medical School, University of São '
'Paulo, Ribeirão Preto, Brazil.'}]},
{ 'given': 'Antonio Carlos',
'family': 'Santos',
'sequence': 'additional',
'affiliation': [ { 'name': 'Department of Medical Imaging, Hematology, and Clinical '
'Oncology, Ribeirão Preto Medical School, University of São '
'Paulo, Ribeirão Preto, Brazil.'}]},
{ 'given': 'Geraldo',
'family': 'Busatto Filho',
'sequence': 'additional',
'affiliation': [ { 'name': 'Laboratory of Psychiatric Neuroimaging (LIM 21), Department of '
'Psychiatry, Faculty of Medicine, University of São Paulo, São '
'Paulo, Brazil.'}]},
{ 'given': 'Jaime E.C.',
'family': 'Hallak',
'sequence': 'additional',
'affiliation': [ { 'name': 'Department of Neuroscience and Behavior, Ribeirão Preto Medical '
'School, University of São Paulo, Ribeirão Preto, Brazil.'},
{ 'name': 'National Institute for Science and Technology—Translational '
'Medicine, São Paulo, Brazil.'}]},
{ 'name': 'for the Cannabidiol for COVID-19 Patients (CANDIDATE) Trial Investigators',
'sequence': 'additional',
'affiliation': []}],
'member': '278',
'published-online': {'date-parts': [[2021, 10, 7]]},
'reference': [ {'key': 'B1', 'doi-asserted-by': 'publisher', 'DOI': '10.1159/000510799'},
{'key': 'B2', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/j.bbi.2020.04.079'},
{'key': 'B3', 'doi-asserted-by': 'publisher', 'DOI': '10.1111/bph.15157'},
{'key': 'B4', 'doi-asserted-by': 'publisher', 'DOI': '10.1089/can.2019.0060'},
{'key': 'B5', 'doi-asserted-by': 'publisher', 'DOI': '10.3390/ijms22041986'},
{'key': 'B6', 'doi-asserted-by': 'publisher', 'DOI': '10.3389/fimmu.2020.613613'},
{'key': 'B7', 'doi-asserted-by': 'publisher', 'DOI': '10.1089/can.2020.0043'},
{ 'key': 'B8',
'first-page': '251',
'volume': '843',
'author': 'Khodadadi H',
'year': '2019',
'journal-title': 'J Cell Mol Med'},
{'key': 'B9', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/j.neuroscience.2014.12.051'},
{'key': 'B10', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/j.nbd.2013.06.016'},
{'key': 'B11', 'doi-asserted-by': 'publisher', 'DOI': '10.1002/glia.23738'},
{'key': 'B12', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/j.bbi.2018.09.014'},
{'key': 'B13', 'doi-asserted-by': 'publisher', 'DOI': '10.1038/s41598-021-81049-2'},
{'key': 'B14', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/j.ejphar.2018.11.029'},
{'key': 'B15', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/j.ijbiomac.2020.12.020'},
{'key': 'B16', 'doi-asserted-by': 'publisher', 'DOI': '10.1111/j.1476-5381.2009.00521.x'},
{'key': 'B17', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/j.jpsychires.2012.08.012'},
{'key': 'B18', 'doi-asserted-by': 'publisher', 'DOI': '10.1017/S1461145712001502'},
{'key': 'B19', 'doi-asserted-by': 'publisher', 'DOI': '10.1038/npp.2011.6'},
{'key': 'B20', 'doi-asserted-by': 'publisher', 'DOI': '10.3389/fpsyg.2019.02466'},
{'key': 'B21', 'doi-asserted-by': 'publisher', 'DOI': '10.1097/JCP.0000000000001405'},
{'key': 'B23', 'doi-asserted-by': 'publisher', 'DOI': '10.1001/jama.2020.6775'},
{'key': 'B25', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/j.jns.2013.06.033'},
{'key': 'B26', 'doi-asserted-by': 'publisher', 'DOI': '10.1183/13993003.00990-2020'},
{'key': 'B27', 'doi-asserted-by': 'publisher', 'DOI': '10.1109/RBME.2020.2990959'},
{'key': 'B28', 'doi-asserted-by': 'publisher', 'DOI': '10.9788/TP2016.1-25'},
{'key': 'B29', 'doi-asserted-by': 'publisher', 'DOI': '10.1111/j.1744-6163.2009.00224.x'},
{'key': 'B30', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/j.thromres.2020.05.006'},
{'key': 'B31', 'doi-asserted-by': 'publisher', 'DOI': '10.1111/eci.13404'},
{'key': 'B32', 'doi-asserted-by': 'publisher', 'DOI': '10.3389/fimmu.2018.02009'}],
'container-title': ['Cannabis and Cannabinoid Research'],
'original-title': [],
'language': 'en',
'link': [ { 'URL': 'https://www.liebertpub.com/doi/full-xml/10.1089/can.2021.0093',
'content-type': 'application/xml',
'content-version': 'vor',
'intended-application': 'text-mining'},
{ 'URL': 'https://www.liebertpub.com/doi/pdf/10.1089/can.2021.0093',
'content-type': 'unspecified',
'content-version': 'vor',
'intended-application': 'similarity-checking'}],
'deposited': { 'date-parts': [[2021, 10, 9]],
'date-time': '2021-10-09T21:02:18Z',
'timestamp': 1633813338000},
'score': 1,
'subtitle': [],
'short-title': [],
'issued': {'date-parts': [[2021, 10, 7]]},
'references-count': 30,
'alternative-id': ['10.1089/can.2021.0093'],
'URL': 'http://dx.doi.org/10.1089/can.2021.0093',
'relation': {},
'ISSN': ['2578-5125', '2378-8763'],
'issn-type': [{'value': '2578-5125', 'type': 'print'}, {'value': '2378-8763', 'type': 'electronic'}],
'subject': ['Pharmacology (medical)', 'Complementary and alternative medicine', 'Pharmacology'],
'published': {'date-parts': [[2021, 10, 7]]}}
